OncologyPRO, in partnership with medwireNews, brings you updates each day in the field of medical oncology.
Watch leading oncology experts in ESMO's latest scientific and educational videos.
Collection of links to the latest cancer related articles in top medical journals: Annals of Oncology, The Lancet, JAMA, NEJM, BMJ and Nature Medicine
Haven't had much time lately? Here's what you may have missed in the last few months
Webcasts produced by leading oncology experts
New! Read patient cases produced by oncology experts or create and store your own cases
Find here all the information related to anti-cancer agents as described in the ESMO Handbook on Clinical Pharmacology of Anti-Cancer Agents.
Number of factsheets of validated biomarkers designed to assist you in your daily practice.
ESMO Clinical Trial Resources are designed to support you with designing, participating in and reviewing clinical trials
Find all ESMO 2014 abstracts classified by drug.
Find the most common oncology abbreviations.
Meeting reports from past ESMO organised and ESMO supported meetings.
Annotated links to the top biomarker journals related to oncology, as per the latest impact factor ranking and open access journals on biomarkers.
Educational slides on Cancer Prevention, Clinical Trials, Colorectal Cancer and Molecular Biology
The 2016 edition of ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology is now available
Our 2016 Clinical Practice Guidelines are now online.
Download the new version of our App with the latest Pocket Guidelines for professionals and Guides for Patients
Information, treatment algorithms and educational materials for healthcare professionals and patients about skin problems that may occur when being treated with anti-EGFR drugs
Information, treatment algorithms and educational materials for healthcare professionals and patients relating to the management of dermatological toxicities in patients treated with multikinase inhibitors.
Information and education online resource for healthcare professionals on drug-drug interactions which can arise from the use of kinase inhibitors
ESMO has developed a set of organ-specific tools designed to assist oncologists in their daily practice.
ESMO Consensus Conferences discuss key questions in certain disease areas and complement the ESMO Clinical Practice Guidelines
Useful information and updates created by ESMO for cancer patients
ESMO members: the recent ESMO Handbooks are available for browsing online to allow you to easily access the sections most relevant to you.
A simplified yet comprehensive overview on oncological malignancies, their biology, diagnosis, staging, treatment and follow-up, which are necessary for basic patient treatment
ESMO members: Browse through the ESMO Glossary in Molecular Biology of Cancer and Molecular Techniques online
Discover the User's Manual for Oncology Clinicians: “Clinician’s notes” for each of the 16 chapters of the patient guide.
Here, ESMO members can gain direct access to journals available to them for free (Annals of Oncology, Nature Reviews Cancer, Nature Reviews Clinical Oncology, and British Journal of Cancer). You can also find links to interesting journals in the fields of Medical Oncology, Haematology and Biomarkers.
Atezolizumab OS Benefit Shown For Stage IIIB–IV Previously Treated NSCLC
Osimertinib Response Shown in EGFR T790M-Positive NSCLC Patients
IMPRESS Results Show ‘Detrimental Effect’ From Continuing Gefitinib After Progression
Alectinib Promising Against CNS Metastases In ALK-Positive NSCLC Patients
Evidence Accumulates For Ceritinib Activity In Heavily Pretreated ALK-Rearranged NSCLC
ASCEND-1 Further Supports Ceritinib In ALK Inhibitor-Naive And -Pretreated NSCLC
Second-Line Atezolizumab Extends Survival In Locally Advanced, Metastatic NSCLC
Afatinib Active in NSCLC Tumours Harbouring Specific Rare EGFR Mutations
Maintenance strategies in stage IV non-small-cell lung cancer (NSCLC): in which patients, with which drugs?
Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer
Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts
Early stage non-small-cell lung cancer: challenges in staging and adjuvant treatment
Vaccination therapy for non-small-cell lung cancer: review of agents in phase III development
Targeting EGFR T790M in NSCLC
How to select the patients with NSCLC for immunotherapy?
Rare molecular events and difficult targets in NSCLC
ESMO Preceptorship on NSCLC Singapore December 2016
European Lung Cancer Conference (ELCC) 2016
ESMO Preceptorship on Lung Cancer 2016
ESMO Preceptorship on NSCLC, 2015, Singapore
ESMO Preceptorship on NSCLC 2015
European Lung Cancer Conference (ELCC) 2015
3rd Symposium on Thoracic and Upper Aerodigestive Malignancies
13th Annual British Thoracic Oncology Group Conference 2015
ESMO 2014 - NSCLC, early stage
ESMO 2014 - NSCLC, locally advanced
ESMO 2014 - NSCLC, metastatic
ESMO 2014 - SCLC
ESMO 2014 - Thoracic malignancies, other
4th International Conference on Thoracic Oncology
ELCC - European Lung Cancer Conference 2014
ESMO-Christie Lung Cancer Course 2014
ESMO Essentials for Clinicians: Thoracic Tumours
ESMO Consensus Conference: Locally-advanced stage III non-small-cell lung cancer (NSCLC)
2015 European Cancer Congress – Scientific Meeting Report Lung Cancer Extract
ESMO 2014 Congress Scientific Meeting Report - Lung Cancer Extract
ELCC 2014 Meeting Report
ESMO Consensus Conference in Lung Cancer: Pathology and molecular biomarkers for NSCLC
ESMO Consensus Conference in Lung Cancer: NSCLC first-line/second and further lines in advanced disease
ESMO Consensus Conference in Lung Cancer: Early stage NSCLC consensus on diagnosis, treatment and follow-up
ESMO Consensus Conference in Lung Cancer: Metastatic NSCLC
ESMO Consensus Conference in Lung Cancer: SCLC
Lung Cancer in the Elderly: A chapter from ESMO Handbook of cancer in the senior patient
Thymic Epithelial Tumours
Malignant Pleural Mesothelioma
Metastatic non-small-cell lung cancer (NSCLC)
Early stage and locally advanced NSCLC
Small-cell lung cancer
Thoracic Oncology Highlights 2014
Important Pathways to Target in (Advanced) NSCLC: A Focus on ALK, EGFR-Inhibition and Anti-Angiogenesis and their Implications for Clinical Practice
The importance of molecular aspects to make therapeutic decisions in lung cancer
PD-L1 in Cancer: ESMO Biomarker Factsheet
EGFR in Lung Cancer: ESMO Biomarker Factsheet
ALK in Lung Cancer: ESMO Biomarker Factsheet
ROS1 in Lung Cancer: ESMO Biomarker Factsheet
From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma
Epidermal growth factor receptor (EGFR) inhibitors and derived treatments
Going beyond EGFR (ALK, ROS1, BRAF, KRAS, HER2, PIK3Ca, MET)
Can sensitivity to cytotoxic chemotherapy be predicted by biomarkers?
Access the latest OncologyPRO content on Lung and other Thoracic Tumours.
Access test questions